针对脂质和炎症的最佳医学疗法,用于在接受皮肤冠状动脉干预的患者中进行二次预防
Imma Forzano1, Domenico Florimonte1, Viviana Narciso1
1Department of Advanced Biomedical Sciences, Federico II University of Naples, 80131 Naples, Italy.
Journal of clinical medicine
|December 11, 2025
概括
接受皮肤冠状动脉干预 (PCI) 的患者面临心血管事件的高残留风险. 针对动脉动脉脂和血管炎症的最佳医疗治疗对于这种高危人群的二次预防至关重要.
科学领域:
- 心脏病学 心脏病学
- 血管生物学 血管生物学
- 预防医学 预防医学
背景情况:
- 心血管疾病 (CVD),主要是冠状动脉疾病 (CAD),是全球主要的死亡和发病原因.
- 动脉样硬化,CAD的潜在病理,涉及慢性斑块的发展,导致慢性冠状动脉综合征 (CCS) 或急性冠状动脉综合征 (ACS).
- 经过皮肤冠状动脉干预 (PCI) 病史的患者,尽管使用目前的标准治疗方法,但仍有随后心血管事件的高风险.
研究的目的:
- 对接受PCI的患者的二次预防策略的现有证据进行审查.
- 突出最佳医疗疗 (OMT) 在管理残留风险中的作用.
- 专注于治疗点,包括动脉质脂质和血管炎症.
主要方法:
- 对PCI后患者的二次预防最近证据的文献综述.
- 分析指南导向疗法及其局限性.
- 检查针对脂质和炎症的新兴治疗方法.
主要成果:
- 尽管有指导方针导向的治疗,但PCI后的患者仍然存在残留风险.
- 动脉性脂质和血管炎症被确定为这种残留风险的关键驱动因素.
- 专注于这些因素的最佳医疗疗 (OMT) 显示出减轻风险的前景.
结论:
- 在PCI后的高风险患者中,对先进的治疗策略有显著的未满足需求.
- 准脂质和炎症是二次预防的关键途径.
- 综合的残留风险管理对于减少这种人群中缺血事件至关重要.
相关概念视频
01:26Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293
01:28Acute Coronary Syndrome IV: Interprofessional Care
197
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
197
01:27Coronary Artery Disease V: Interprofessional Care
203
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
203
01:27Peripheral Artery Disease III: Interprofessional Care
221
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
221
01:26Angina IV: Management
215
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
215
01:26Coronary Artery Disease IV: Preventive Measures
572
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
572